Your email was addressed as a survey and the only link was the one I am responding to now.
To question #1; Did I receive the medication shipment as ordered?
The answer is yes, and I was impressed with the time in which it was delivered to my home; only 10 days!
To question #2; did the medication meet my expectations?
Again the answer is yes! I was also impressed with your website which explains everything about ordering outside the U.S., quality of the medication made at the India labs, number(s) to call if the shipment is held up in Customs, and the ease in placing the order.
- Dave
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for ... - MarketWatch (press release)
Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for .
New Nd:YAG laser delivery option manages onychomycosis, study shows - ModernMedicine
New Nd:YAG laser delivery option manages onychomycosis, study showsModernMedicineThough they have a proven efficacy, oral antifungal therapies used in onychomycosis such as terbinafine (Lamisil, Novartis) and itraconazole (Sporanox, Janssen) can have significant adverse events, including potential hepatic toxicity.
Novartis to buy Fougera Pharma for $1.5 bln - Stock Market Digital
Novartis to buy Fougera Pharma for $1.
Interview With The President And CEO: Apricus Biosciences, Inc. (APRI ... - The Wall Street Transcript
Interview With The President And CEO: Apricus Biosciences, Inc.
붙이는 조백선 치료제 3상 임상서 효과 미흡 - 메디파나뉴스
붙이는 조백선 치료제 3상 임상서 효과 미흡메디파나뉴스일본 히사미츠제약이 조백선 치료제로 개발을 추진하고 있는 'HTU-520'(terbinafine)이 3상 임상시험에서 기대한 만큼의 효과를 얻지 못한 것으로 나타났다.